Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects

S. SubhashChandran, N. Syed, A. Jakkanwar, J. Yewale, S. Bommera, J. Po, S. Chahad, S. Purandare, A. Lulla, A. Sule (Mumbai, India)

Source: Annual Congress 2009 - New aspects of inhalation therapy
Session: New aspects of inhalation therapy
Session type: Thematic Poster Session
Number: 2042
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. SubhashChandran, N. Syed, A. Jakkanwar, J. Yewale, S. Bommera, J. Po, S. Chahad, S. Purandare, A. Lulla, A. Sule (Mumbai, India). Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects. Eur Respir J 2009; 34: Suppl. 53, 2042

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Budesonide pharmacokinetics and systemic effects at steady state via HFA pMDI, CFC pMDI and Turbuhaler® in healthy volunteers
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008


Systemic effects and pharmacokinetics of a new CFC-free metered dose inhaler of beclomethasone dipropionate following multiple dosing in asthmatic patients
Source: Eur Respir J 2005; 26: Suppl. 49, 180s
Year: 2005

Pharmacokinetic evaluation of two HFA pMDI formulations of salmeterol xinafoate administered through a spacer in healthy subjects
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD
Source: ERJ Open Res, 6 (2) 00187-2019; 10.1183/23120541.00187-2019
Year: 2020



Pharmaceutical development of salmeterol HFA metered dose inhaler
Source: Eur Respir J 2004; 24: Suppl. 48, 582s
Year: 2004

Assessment of relative potency of salbutamol administered via a metered-dose inhaler plus spacer or via a dry-powder inhaler in asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 209s
Year: 2006

Bronchodilator response to salbutamol administered through metered-dose inhaler plus spacer or dry-powder inhaler in asthmatic patients
Source: Eur Respir J 2001; 18: Suppl. 33, 101s
Year: 2001

Comparison of proficiency of pressurized metered dose inhaler (pMDI) use with asthma control
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008


Systemic activity of beclometasone dipropionate HFA and CFC formulations in metered dose inhalers assessed by knemometry
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010

Efficacy and safety of budesonide/formoterol fumarate dihydrate metered dose inhaler (BFF MDI) using co-suspension delivery technology compared to monocomponents and an active comparator in COPD
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018


Evaluation of the systemic pharmacodynamic effects of two HFA formulations of Salmeterol xinafoate/Fluticasone propionate HFA pMDI 25/250 mcg
Source: International Congress 2017 – Inhalers and their use
Year: 2017

Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012


Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma
Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies
Year: 2020


Improvement in the drug delivery of salmeterol/fluticasone via a novel breath actuatedpressurized metered dose inhaler with a dose counter
Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies
Year: 2019

Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects
Source: Eur Respir J 2001; 18: Suppl. 33, 50s
Year: 2001

Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 311s
Year: 2003

Pharmacokinetic and pharmacodynamic characteristics of HFA and CFC pMDI formulations of budesonide
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010


Effect of the actuator orifice diameter on the biodisposition of a new budesonide CFC-free metered dose inhaler formulation
Source: Eur Respir J 2001; 18: Suppl. 33, 102s
Year: 2001

Oral manifestations in asthmatic patients using metered dose inhaler and dry powder inhaler
Source: International Congress 2019 – Innovations in primary care assessment and management
Year: 2019

Objective measurement of inhalation profiles in patients using metered dose inhalers (MDIs)
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011